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Purpose: Rational modification of promoter architecture is necessary for manipulation of transgene activity and requires
accurate deciphering of regulatory control elements. Identification of minimally sized promoters is critical to the design
of viral vectors for gene therapy. To this end, we evaluated computational methods for predicting short DNA sequences
capable of driving gene expression in Müller cells.
Methods: We measured enhanced green fluorescent protein (eGFP) expression levels driven by “full-length” promoters,
and compared these data with computationally identified shorter promoter elements from the same genes. We cloned and
screened over 90 sequences from nine Müller cell-associated genes: CAR2, CD44, GFAP, GLUL, PDGFRA, RLBP1,
S100B, SLC1A3, and vimentin (VIM). We PCR-amplified the “full-length” promoter (~1500 bp), the proximal promoter
(~500 bp), and the most proximal evolutionarily conserved region (ECR; 95–871 bp) for each gene, both with and without
their respective 5′ untranslated regions (UTRs), from C57BL/6J mouse genomic DNA. We selected and cloned additional
ECRs from more distal genomic regions (both 5′ and 3′) of the VIM and CD44 genes, using both mouse and rat (Sprague-
Dawley) genomic DNA as templates. PCR products were cloned into the pFTMGW or pFTM3GW lentiviral transfer
vectors. Plasmid constructs were transfected into rat (wMC) or human (MIO-M1) Müller cells, and eGFP expression
levels were evaluated by fluorescence microscopy and flow cytometry. Selected constructs were also examined in NIH/
3T3 and Neuro-2a cells.
Results: Several ECRs from the nine Müller cell-associated genes were able to drive reporter gene expression as well as
their longer counterparts. Preliminary comparisons of ECRs from the VIM and CD44 genes suggested that inclusion of
UTRs in promoter constructs resulted in increased transgene expression levels. Systematic comparison of promoter activity
from nine Müller cell-expressed genes supported this finding, and characteristic regulation profiles were evident among
the different genes tested. Importantly, individual cloned promoter sequences were capable of driving distinct levels of
transgene expression, resulting in up to eightfold more cells expressing eGFP with up to 3.8-fold higher mean fluorescence
intensity (MFI). Furthermore, combining constructs into single regulatory “units” modulated transgene expression,
suggesting that secondary gene sequences provided in cis may be used to fine-tune gene expression levels.
Conclusions: In this study, we demonstrate that computational and empirical methods, when used in combination, can
efficiently identify short promoters that are active in cultured Müller cells. In addition, the pFTM3GW vector can be used
to study the effects of combined promoter elements. We anticipate that these methods will expedite the design and testing
of synthetic/chimeric promoter constructs that should be useful for both in vitro and in vivo applications.
Therapeutic treatment of dominant disease in the human
retina  has  yet  to  be  attempted.  Given  the  extreme
heterogeneity of retinal diseases (RetNet), effective therapies
will likely require more sophisticated vector designs than are
currently available for gene augmentation of recessive null
mutations. One of the major challenges in engineering any
genetic therapy is to design a transgene cassette that enables
precise regulatory control of gene expression while abiding
by  the  size  constraints  of  the  virus’  packaging  limit.
Expression  of  transgenes  by  targeted  cells  requires
coordination  of  gene  delivery,  nuclear  localization,  and
subsequent harnessing of the cell’s transcriptional machinery.
Though viral targeting of retinal cells has improved in recent
years [1,2], a critical aspect of any gene therapy is how to
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control  the  specificity  and  expression  levels  of  the  gene
product being expressed [3] once it is delivered to the proper
cell.
Progress  in  achieving  precise  control  over  transgene
expression is hampered by an incomplete understanding of the
underlying genetic mechanisms influencing endogenous gene
expression [4]. In recent years, numerous promoters have
been characterized and used to confer inducible, constitutive,
cell  specific,  as  well  as  temporal  transgene  expression  to
retinal (and many other) cells. However, experimental gene
augmentation  strategies  often  utilize  strong,  constitutive
promoters  for  driving  transgene  expression  in  retinal
photoreceptors,  retinal  ganglion  cells,  and  pigmented
epithelial  cells  [5–7].  There  is  concern  that  promiscuous,
high-expression promoter elements, such as cytomegalovirus
(CMV) and chicken beta actin (CBA) [6,7], can generate
undesirable  and  toxic  gene  expression,  particularly  when
“bioactive” molecules are delivered. Although robust gene
expression is often preferable for reporter gene-associated
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691assays used in the laboratory, improved precision and control
of gene expression levels will be crucial for human therapies.
To  this  end,  novel  approaches  are  being  considered  for
controlling expression levels in diverse cellular contexts [8,
9], and synthetic control over viral transgene expression in
retinal gene therapy applications is now feasible [10–14].
In addition to imparting improved control overexpression
levels, it is critical to identify promoters that are small enough
to be efficiently packaged into viral capsids [15]. For example,
adeno-associated virus (AAV), which has a relatively small
(~4.7  kb)  packaging  limit  [16],  continues  to  be  the  most
widely considered virus for treating eye disease [5,7]. There
are  currently  no  reliable  methods  for  predicting  how  the
primary  gene  sequence  and  nuclear  microenvironment(s)
combine to direct, control, and regulate gene expression [17].
Nevertheless,  recent  advances  in  computational  genomics
have provided valuable tools for cross-genome data mining,
and have made promoter selection less empirical [18–20].
These  online  bioinformatics  tools  generally  provide
alignments of whole genes as well as chromosomes and allow
for rapid identification of evolutionarily conserved regions
(ECRs): small stretches of genomic DNA (gDNA) that have
survived  prolonged  selective  pressure  and  presumably
contribute to proximate gene expression. These sequences
typically  contain  conserved,  empirically  annotated
transcription factor binding sites, which likely contribute to
mRNA expression by influencing both expression levels and
cellular specificity [18,21]. Therefore, identification of ECRs
from regulatory regions of genes with restricted expression
patterns, i.e., in a targeted cell type, is a logical starting point
in the search for compact promoters for viral gene therapy.
Previously [22] we modified a self-inactivating lentiviral
(LV)  transfer  vector,  pFUGW  [23,24],  to  facilitate  the
throughput, cloning, and evaluation of novel, computationally
identified promoter constructs. In the current study, promoters
and  ECR  promoter  fragments  from  nine  Müller  cell-
associated  genes  were  cloned  into  our  modified  vector
(pFTM3GW) and studied by transfection and flow cytometry
(accession numbers refer to Mus musculus genes): carbonic
anhydrase  II  (CAR2;NM_009801)  [25];  CD44
(NM_009851)  [26];  glial  fibrillary  acidic  protein
(GFAP;NM_010277)  [27];  glutamate-ammonia  ligase
(GLUL;NM_008131;  historically  referred  to  as  glutamine
synthetase, GS) [28]; platelet derived growth factor receptor,
alpha  polypeptide  (PDGFRA;NM_011058)  [29];
retinaldehyde binding protein 1 (RLBP1;NM_020599) [30];
S100 protein, beta polypeptide, neural (S100B;NM_009115)
[31,32]; solute carrier family 1 (glial high affinity glutamate
transporter), member 3 (SLC1A3;NM_148938; historically
referred to as glutamate-aspartate transporter, GLAST) [33,
34]; and vimentin (VIM;NM_011701) [35].
METHODS
Vector design: We modified a LV transfer vector (pFTMGW)
[22] by adding restriction sites and enhancing the multiple
cloning site (MCSv3); the new vector was named pFTM3GW
(Figure 1). Briefly, we replaced the original multiple cloning
site (MCS) in pFTMGW with MCSv3, in which the order of
the 12 unique restriction sites was modified (5′-PacI-AsiSI-
BlpI-RsrII-SwaI-AscI-HpaI-BsiWI-SdaI-NheI-BstEII-
BamHI-3′) to facilitate double-digestion reactions (the BsiWI
site  was  newly  added).  In  addition,  we  flanked  the
transcription blocker (TB) with an additional BstBI restriction
site,  facilitating  rapid  removal  of  the  TB  before  LV
production. Finally, the hCMV/LTR hybrid promoter was
modified such that it was flanked by SpeI endonuclease sites,
allowing for efficient removal during preliminary candidate
promoter evaluation, if desired.
Candidate sequence selection: Using online bioinformatics
software  (dcode)  we  identified  and  cloned  full-length
promoters (~1500 bp), proximal promoter regions (500 bp),
and the most proximal ECRs, relative to the transcription start
site  (TSS),  for  each  of  nine  Müller  cell  expressed  genes:
CAR2,  CD44,  GFAP,  GLUL,  PDGFRA,  RLBP1,  S100B,
SLC1A3,  and  VIM.  ECR  sequences  were  identified  in
canonical promoter regions mandating a minimum of 70%
sequence homology between human and mouse genomes over
a 100 bp “window.” Based on the observation that several
genes have sizable 5′ untranslated regions (UTRs) containing
numerous transcription factor binding sites, in addition to the
fact  that  5′  UTRs  afforded  improved  expression  in  first-
generation constructs, fragments from each of the nine genes
(1500 bp, 500 bp, and ECR) were cloned with and without
their associated 5′ UTR, or part thereof (see Appendix 1). All
transcription  start  sites  were  identified  using  RefSeq
sequences (NCBI) compiled into single data files available at
(ECRbase). The current mouse (mm8), rat (rn4), and human
(hg18) assemblies of their respective genomes were used for
all sequence comparisons, alignments, and primer design.
Sequence  analysis  and  primer  design:  DNA  sequences
identified using the ECR Browser were imported into Vector
NTI (VNTI; Invitrogen, Carlsbad, CA). Primers were selected
using VNTI primer design software, and one or two restriction
sites were manually added to the 5′ ends of each primer to
confer additional flexibility in the cloning process and to allow
constructs to be cloned into different regions of the MCS in
the pFTM3GW vector (see Appendix 1 and Appendix 2).
Primers from Operon Technologies (Huntsville, AL) were
resuspended at 100 µM in 10 mM Tris (pH 8.0) and 1 mM
EDTA.
Polymerase  chain  reaction  amplification  and  cloning:
Sequences were PCR-amplified from C57BL/6J mouse or
Sprague-Dawley rat gDNA using 0.5 U per reaction Platinum
Taq or Platinum Taq High-Fidelity Polymerases (Invitrogen).
Standard reaction conditions were 2.5 mM Mg2+, 0.2 µM each
primer, 0.2 mM deoxyribonucleotide triphosphates (dNTPs),
and 10–50 ng gDNA in a 20 µl reaction volume. A list of
cloned sequences, including their primer sequences and their
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and Appendix 2. PCR products were typically T/A cloned into
the  pGemT-Easy  vector  (Promega,  Madison,  WI)  and
transformed  into  DH5alpha  chemically  competent  cells
(Invitrogen). Plasmid DNA was isolated using the QIAprep
Miniprep Kit (Qiagen Corp., Valencia, CA). Each promoter
fragment was digested and gel purified from pGem-T-easy,
and subsequently subcloned into linearized pFTM3GW. For
verification, all constructs were PCR screened, endonuclease
digested,  and  sequenced.  While  most  promoter  sequences
matched  published  database  sequences  exactly,  some
sequences had individual point mutations as well as small (1
or  2  bp)  insertions  or  deletions,  particularly  in  genomic
regions containing a minisatellite repeat(s).
Cell culture and transfection: Cell culture was performed as
previously described [22] for both rat (wMCs) and human
(MIO-M1) Müller cells [36]. MIO-M1 cells were a gift from
University College London. NIH/3T3 (ATCC#: CRL-1658)
and Neuro-2a (ATCC#: CCL-131) were obtained from the
University  of  California,  Berkeley  core  research  facility.
Briefly, approximately 200,000 Müller cells or 400,000 NIH/
3T3 or Neuro-2a cells were plated per well on 12 well plates.
Cells were grown in Dulbecco's Modified Eagle's Medium
(DMEM) including high glucose (Invitrogen) with 10% fetal
bovine  serum  (FBS;  HyClone;  Thermo  Fisher  Scientific,
Waltham, MA) and 4 mM L-glutamine without antibiotics
until they reached 90% confluence (~24 h). A transfection
complex with 0.75 µg plasmid DNA (experimental or control)
and 3.75 µl Lipofectamine 2000 (Invitrogen) in 200 µl of
OptiMEM  (Gibco;  Invitrogen)  medium  was  prepared
according  to  the  manufacturer’s  specifications.  Growth
medium  was  removed  and  the  transfection  complex  was
added into each individual well. After 10 min, 1 ml of fresh
media without antibiotics was added. Cells were cultured for
approximately 40 h before flow cytometry analysis.
Flow  cytometry  and  data  analysis:  Methods  for  flow
cytometry  and  fluorescence  microscopy  were  described
previously  [22].  Briefly,  transfected  wMC  and  MIO-M1
Müller cells were trypsinized for ~3–5 min, resuspended in
500 µl DMEM media, and maintained on wet ice. At least
20,000 cell counts were collected for each sample, and three
independent samples were counted for each construct. Mean
fluorescence intensity (MFI) and percent eGFP positive cells
were calculated and collected for each sample under identical
gating  conditions  within  each  experiment.  All  data  were
normalized to the promoter-less parent vector (pFTMGW or
pFTM3GW) or pFUGW, and were subsequently plotted as
relative fold-change in terms of number of eGFP labeled cells
and  MFIs.  pFTM3GW  and  pFTMGW  [22]  employ  a  TB
element to minimize (by 85%–90%) transgene expression by
an  upstream  hybrid  CMV/5′LTR  promoter,  which  is
necessary for virus production. The fortuitous “leakiness” of
Figure  1.  The  pFTM3GW  lentiviral
transfer  vector.  The  pFTM3GW
plasmid  vector  was  constructed  by
adding  restriction  sites  to  the  parent
plasmid,  pFTMGW.  A  SpeI  site  was
added  to  the  5′  end  of  the  hCMV
enhancer, and a BstBI site was added to
the 3′ end of the TB; both modifications
duplicate existing sites on the opposite
sides  of  the  genetic  elements,
simplifying  removal  of  the  elements
when  desired.  We  also  reordered  the
restriction sites in the multiple cloning
site (MCS) to facilitate double-digestion
reaction  performance  and  subsequent
cloning. ColE1 ori (bacterial origin of
replication)  and  AmpR  (ampicillin
resistance gene) were used for plasmid
replication.  The  enhanced  green
fluorescent  protein  (eGFP)  is  the
reporter molecule. The cytomegalovirus
promoter (CMV), long-terminal repeats
(LTRs),  splice  donor  and  viral
packaging  sequences  (SD/Psi),  Rev
Response  element  (RRE),  central
polypurine  tract  (CPPT)  and
Woodchuck  hepatitis  virus  post-
transcriptional  regulatory  element
(WPRE) are viral elements.
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693the TB element has two benefits: 1) it allows for efficient and
accurate normalization across experiments; and 2) it allows
for the identification of MCS-cloned elements that negatively
influence transgene expression. We used Microsoft Excel for
all  statistical  analyses,  using  the  Student's  t-test  for  all
comparisons  (two-sample  assuming  equal  variances).
Analyses were performed on raw data counts and collected as
percent positive cells (fluorescent, flow cytometry counted).
Data and errors were normalized to the promoter-less parent
vectors (pFTMGW or pFTM3GW) or pFUGW. Data obtained
from control plasmid transfections were set to a value of 1.0
(or 100%), which allowed for relative fold-change (increase
or decrease) calculations for experimental constructs, as well
as a baseline for comparison between experiments. All error
bars represent (±) 1 standard deviation.
Microscopy:  For  microscopic  examination  of  eGFP
expression, cells were grown on cover glass under identical
conditions, and were processed as previously described [22].
Briefly, cells were transfected for approximately 24 h, rinsed
with phosphate buffered saline (PBS; pH 7.4), fixed with 10%
neutral buffered formalin for 15 min, rinsed again with PBS,
and  inverted  on  a  microscope  slide  containing  a  drop  of
Vectashield  (Vector  Laboratories,  Inc.,  Burlingame,  CA)
containing  DAPI  (4',6-diamidino-2-phenylindole)  as  a
Figure  2.  Flow  cytometry  analysis  of
promoter fragments from nine Müller
cell expressed genes. A: Diagrammatic
representation  of  DNA  fragments
analyzed here and in subsequent figures.
B-J:  Significant  variability  in  both
number  of  positive  cells  and
fluorescence  intensity  are  apparent
among the 61 fragments tested. Seven
fragments were analyzed for each gene:
the 5′ UTR alone (yellow), a ~1500 bp
(red), a ~500 bp (green), and a variable-
sized  evolutionarily  conserved  region
(ECR; blue), each with and without their
respective 5′ UTRs. Bars indicate fold
change  in  number  of  eGFP  positive
cells, normalized to the promoter-less
parent vector (pFTM3GW). The mean
fluorescence  intensity  (MFI)  for  each
construct  was  also  normalized  to  the
parent  vector  (pFTM3GW)  and  is
shown  immediately  below  each  bar
(shown  in  orange).  UTRs  for  the
GFAP (14 bp) and CAR2 (28 bp) genes
were  quite  short  and  not  individually
tested. Both the locationrelative to the
transcriptional start site (TSS), and the
size  of  the  ECRs  vary  for  each  gene
(official gene names can be found in
Introduction). Refer to Appendix 1 for
genomic coordinates of each construct.
The  symbol  (§)  identifies  ECRs  that
were not immediately adjacent to the
TSS (CD44, GFAP, RLBP1, and VIM),
and less-conserved DNA between the
ECR and TSS was included for each of
these constructs. ATG is the codon for
the  starting  methionine.  Error  bars
represent  1  standard  deviation.  The
single asterisk equals p<0.01, the double
asterisk equals p<0.001, and the triple
asterisk equals p<0.0001, using a two-
tailed  Student's  t-test  assuming  equal
variances. ND means “not determined.”
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694nuclear counterstain (blue). Images were collected using Zeiss
Axiovision 4.4 software (Carl Zeiss, Oberkochen, Germany)
with a fixed exposure time, and all images were identically
post-processed with Adobe Photoshop (Adobe Systems, San
Jose, CA).
RESULTS
Control plasmids and normalization: The pFTM3GW LV
transfer vector (Figure 1) is an improved version of pFTMGW
[22]  (see  Methods  for  details).  This  vector  utilizes  a  TB
element to greatly reduce expression (by 85%–90%) from the
hybrid hCMV/5′LTR (a promoter element required for in vitro
virus production). In each of the experiments presented here,
we utilize the low basal level of “read-through” expression
(~10%–15%) as our baseline for normalization, except for the
comparative expression in NIH/3T3 and Neuro-2a cells, for
which the pFUGW plasmid (containing a portion of the human
ubiquitin-C promoter) was used for normalization. Thus, the
percentage of eGFP positive cells counts for pFTMGW or
pFTM3GW control plasmids were assigned a value of 1.0, and
all measurements of experimental constructs are shown in
terms  of  fold  change  (in  number  of  eGFP  positive  cells)
relative to pFTMGW, pFTM3GW, or pFUGW. In addition,
all MFI's were similarly normalized: these data are indicated
in  each  graph  immediately  under  each  bar  (shaded  with
orange).  Lastly,  the  “leakiness”  of  the  TB  permits  the
identification of putative repressive regulatory elements.
Müller cell-associated promoter testing: We systematically
examined the activity of 61 DNA sequences in the promoter
regions of 9 Müller cell-associated genes (Figure 2, Appendix
1).  Fragments  cloned  from  each  gene  are  schematically
represented in Figure 2A, and numbered relative to the TSS.
We cloned the 500 bp and the 1500 bp sequences, both with
and without the adjacent 5′ UTR, for each of the nine genes
(Figure  2B-2J).  In  addition,  ECRs  were  cloned  with  and
without the 5′ UTR. In some cases (CD44, GFAP, RLBP1,
and VIM; see Appendix 1), the most proximal ECR was not
immediately adjacent to the TSS: when cloning these ECR
+UTR  fragments,  additional  intervening  sequences
possessing less than our 70% homology threshold between the
ECRs  and  5′  UTRs,  including  the  TSSs,  were  included.
Finally, individual UTR sequences for seven of the nine genes
were tested alone. The UTRs for CAR2 (28 bp) and GFAP (14
bp) were quite small, and not individually examined.
Variable influences of the 5′ untranslated regions: In general,
the UTRs alone were capable of increasing the number of
Figure 3. The choice of gene promoter
and  the  presence  of  the  gene’s  5′
untranslated region influence the level
of reporter gene expression in cultured
rat Müller cells. Microscopic analysis is
in agreement with the flow cytometry
data (Figure 2), and therefore serves as
a  rapid,  qualitative  approach  to
screening  experimental  promoters.
eGFP expression is demonstrated for the
500 bp promoter fragments either with
(right) or without (left) the 5′ UTR for
each of the nine genes analyzed (A-I).
Shown in (J) are control transfections
with the backbone vector (pFTM3GW;
left), or a vector containing the 1178 bp
human ubiquitin-C promoter (pFUGW;
right). Scale bar in (A) equals 10 µm.
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695eGFP positive cells two- to sevenfold (Figure 2). RLBP1
(Figure 2G) showed very low expression unless the UTR was
combined with other regulatory elements (500 bp, 1500 bp,
or ECR). Combining RLBP elements (500+UTR, 1500+UTR,
or ECR+UTR) resulted in greater than four- to sevenfold more
Müller cells expressing eGFP, with a concomitant increase in
MFIs (up to 3.6-fold higher; 500+UTR). Similarly for the
S100B gene (Figure 2H), including the UTR led to increased
expression  over  individual  constructs.  For  S100B,  the
combined constructs (500+UTR and ECR+UTR) appeared to
have  more  of  an  “additive”  effect  on  eGFP  expression,
whereas  a  “multiplicative”  influence  was  apparent  for
RLBP1.  The  UTRs  of  CD44  (Figure  2С)  and  PDGFRA
(Figure 2F) drove significant levels of eGFP expression on
their own, whereas the individual 5′ elements (500 bp, 1500
bp,  and  ECR)  resulted  in  considerably  lower  eGFP
expression.
In  contrast,  some  constructs  without  UTRs  drove
significant  levels  of  eGFP  in  cultured  Müller  cells.  For
example, the 500 bp, 1500 bp, and ECR elements in CAR2
(Figure 2B), GFAP (Figure 2D; except ECR), GLUL (Figure
2E),  and  VIM  (Figure  2J)  resulted  in  three-  to  eightfold
changes in the number of cells expressing eGFP. Note that the
118 bp GLUL UTR led to a nominal (approximately twofold)
change  in  reporter  gene  expression  by  itself,  whereas  the
individual constructs (with or without the UTR) resulted in
six- to eightfold increases. Thus, in the case of GLUL, the UTR
appeared to exhibit only a minor influence on gene expression,
whereas  upstream  elements  contributed  significantly.
Constructs isolated from the SLC1A3 gene exhibited variable
influences on eGFP expression (Figure 2I). In contrast to other
genes, the SLC1A3 1500+UTR and 500+UTR sequences led
to reduced expression relative to the 500 bp and 1500 bp
fragments without the UTR (Figure 2I), suggesting a complex
cis-regulatory network involving both positive and negative
influences at the SLC1A3 promoter. Even though the cellular
specificity of these regulatory elements has not been verified,
it is worth noting that the short, 205 bp GFAP ECR+UTR
promoter fragment drove eGFP expression as well as any
other GFAP construct tested (Figure 2D).
Microscopic examination of 500 bp elements: We screened
promoter constructs using fluorescence microscopy before
flow  cytometry  analysis,  and  qualitatively  assessed  their
eGFP expression 24–40 h following transfection. Figure 3
shows fluorescent micrographs of rat Müller cells grown on
cover glass and transfected with the 500 bp and 500+UTR
constructs for each of the nine genes. Cultures were treated
identically to those used for flow cytometry experiments, and
qualitatively  support  the  quantitative  flow  cytometry  data
shown in Figure 2. The presence of the UTR enhanced the
number  of  eGFP-labeled  cells  in  several  experimental
constructs:  CD44  (Figure  3B);  PDGFRA  (Figure  3E);
RLBP1 (Figure 3F); S100B (Figure 3G); and VIM (Figure 3I).
In contrast, little or no effect was observed for CAR2 (Figure
3A), GFAP (Figure 3C), or GLUL (Figure 3D). Lastly, the
presence of the UTR in the SLC1A3 construct (500+UTR;
Figure 3H) resulted in fewer eGFP labeled cells (also see
Figure 2I). Control transfections (Figure 3J) appropriately
exhibited  a  few  dim  (pFTM3GW)  or  numerous  bright
Figure  4.  Comparison  of  promoter
regulated gene expression in rat (wMC)
and  human  (MIO-M1)  Müller  cells.
Müller cells were transfected with 500
bp  or  500+UTR  genomic  DNA
constructs (mouse) from each of the nine
genes analyzed. Expression was more
robust in rat Müller cells (red bars) when
compared with human MIO-M1 Müller
cells (blue bars), although the trends in
promoter-driven  transgene  expression
are similar between species and within
genes.  Bars  indicate  fold  change  in
number  of  eGFP  positive  cells,
normalized to the promoter-less parent
vector  (pFTM3GW).  The  mean
fluorescence  intensity  (MFI)  for  each
construct  was  also  normalized  to  the
parent  vector  (pFTM3GW)  and  is
shown  immediately  below  each  bar
(shown in orange). Refer to Appendix
1  for  genomic  coordinates  of  each
construct.  Error  bars  represent  1
standard deviation.
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696(pFUGW;  containing  the  human  ubiquitin-C  promoter)
fluorescent wMC Müller cells.
Comparison between rat and human Müller cells: To assess
orthologous promoter activity, we applied the same 500 bp
and  500+UTR  promoter  constructs  to  a  spontaneously
generated human Müller cell line (MIO-M1 [36]). Figure 4
indicates fold changes in eGFP positive cells in both rat (red)
and  human  (blue)  cultured  Müller  cells.  All  data  were
normalized to the promoter-less parent plasmid, pFTM3GW
(not  shown).  As  one  might  expect  from  divergent  DNA
promoter sequences, the overall numbers (and MFIs) of eGFP
positive human Müller cells were reduced relative to the rat
(wMC) Müller cells. Importantly, though, the trends in the
data were notably conserved for several genes, suggesting that
some orthologous, sequence-related mechanisms are likely
participating in the reporter gene expression. Some genes
exhibit  similar  expression  profiles  (RLBP1,  S100B,
SLC1A3), while others exhibit definitive differences (CAR2
and GFAP).
Further analysis of the mouse and rat CD44 and vimentin
promoters:  We  computationally  identified,  cloned,  and
screened additional mouse and rat ECR sequences from the
CD44 and VIM genes. A total of 32 ECRs (see Appendix 2)
located both upstream and downstream (typically more distal
conserved regions) of the mouse and rat CD44 and VIM
coding sequences were cloned and studied by either flow
cytometry  or  fluorescence  microscopy  or  both.
Approximately  60%  (20/32)  of  the  individual  constructs
resulted in expression levels that were indistinguishable from
pFTMGW vector alone (see Appendix 2; constructs with “nd”
in the eGFP and MFI columns). After microscopic screening
(data not shown), the remaining ECRs (12/32) were analyzed
by flow cytometry (Figure 5; Appendix 2). Notably, some
ECRs representing the same conserved regions in mouse and
rat drove eGFP expression at similar expression levels (Figure
5;  CD44M2/CD44R2  and  VIMM2/VIMR2).  Both  pairs  of
promoter  constructs  resulted  in  roughly  two-  to  threefold
increases in number of eGFP expressing cells. Interestingly,
the two rodent VIM genes have different TSSs; VIMR2 (rat)
is a 409 bp fragment, containing 330 bp of the VIM promoter
and 79 bp of the VIM 5′ UTR, whereas VIMM2 (mouse) is
entirely within the VIM 5′ UTR. It is also important to notice
the reduction in the number of eGFP positive cells (and MFI)
by  the  VIMR6  and  CD44R4  constructs.  In  particular,  the
VIMR6 fragment negatively influenced eGFP expression by
both flow cytometry (Figure 5) and fluorescence microscopy
(data  not  shown).  Moreover,  when  added  to  the  VIMR2
promoter fragment, VIMR6 reduced the number of wMC
Müller cells by ~33% (Figure 6).
Complex and chimeric promoters are readily testable using
pFTMGW or pFTM3GW: We examined the feasibility of
cloning and testing in silico-designed, conjoined promoter
constructs  (Figure  6).  We  added  secondary  ECRs  to  two
promising plasmid constructs containing VIMR2 or CD44R2
Figure 5. Transfection of mouse and rat
evolutionarily conserved regions from
the VIM and CD44 genes in wMC (rat)
Müller  cells.  Constructs  containing
either  5′  (VIMM2,  VIMR2,  CD44M2,
CD44R2) or 3′ (VIMR7 and VIMR8)
UTRs exhibited high eGFP expression
levels (shown in bold). VIM constructs
are shown in red, and CD44 constructs
are  shown  in  blue;  lighter  colors  are
mouse constructs and darker colors are
rat constructs. Bars indicate fold change
in  number  of  eGFP  positive  cells,
normalized  to  the  “first-generation”
promoter-less  parent  vector
(pFTMGW).  The  mean  fluorescence
intensity (MFI) for each construct was
also  normalized  to  the  parent  vector
(pFTMGW)  [22]  and  is  shown
immediately below each bar (shown in
orange).  Refer  to  Appendix  2  for
genomic coordinates of each construct.
The single asterisk equals p<0.01, the
double asterisk equals p<0.001, and the
triple asterisk equals p<0.0001, using a
two-tailed  Student's  t-test  assuming
equal variances. Error bars represent 1
standard deviation.
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697(both of rat origin). At least for VIMR2 and CD44R2, the
inclusion of additional ECR elements upstream of existing
elements (having already been cloned into the MCS) resulted
in a reduction in the number of eGFP expressing cells. The
chimeric construct, CD44R2 and VIMR2 (red-blue bar), was
not significantly different from either individual construct
with  respect  to  number  of  eGFP  positive  cells  or  MFIs.
Duplicating the VIMR2 element slightly decreased the number
of cells, but did not affect the level of expression (MFI) when
compared  to  the  single  VIMR2  construct.  Directional
selectivity/specificity of the VIMR2 promoter was confirmed
by testing a construct in which VIMR2 was cloned in the
opposite orientation (VIMR2-Reverse; 3′-5′ orientation). The
VIMR2-Reverse construct resulted in slightly fewer eGFP
positive cells (p=.033) when compared to the vector alone
(pFTMGW).
We also identified a short fragment from the rat vimentin
gene  that  appeared  to  negatively  modulate  transgene
expression when tested individually and when included in
combination  with  other  putative  regulatory  elements.  The
VIMR6 sequence lies ~2.8 kb upstream (5′) of the gene’s TSS,
and its specific function remains to be determined. Shown in
Figure 5, the 360 bp VIMR6 ECR fragment decreased the
amount of pFTMGW baseline expression by 45%, suggesting
Figure 6. Compound promoter constructs can modulate transgene expression. Vimentin (VIM) and CD44 evolutionary conserved regions
(ECRs) were tested were tested in various combinations. For both genes, we examined the effect of adding gene-specific ECRs to either of
the VIMR2 or CD44R2 element-containing vectors; in each case the added ECR was positioned 5′ to the existing cloned promoter element
(VIMR2 or CD44R2) within the multiple cloning site (MCS), to the, to the existing promoter element (VIMR2 or CD44R2). Adding VIMR2–
6 to the VIMR2-containing construct resulted in slightly lower number of cells expressing eGFP (shown in red), while the mean fluorescence
intensity (MFI) remained constant. When CD44R3–6 were individually added to CD44R2 (shown in blue), both cell counts and MFIs showed
a modest decrease. The VIMR2-Reverse reduced expression to near baseline levels. A chimeric promoter construct containing VIMR2 (3′)
and CD44R2 (5′) elements (red/blue) did not change expression significantly. Bars indicate fold change in number of eGFP positive cells,
normalized to the “first-generation” promoter-less parent vector (pFTMGW) [22]. The MFI for each construct was also normalized to the
parent vector (pFTMGW) and is shown immediately below each bar (shown in orange). Refer to Appendix 2 for genomic coordinates of each
construct. Compared to pFTMGW, all constructs (except VIMR2R) showed quantitatively different expression. p<0.01, using a two-tailed
Student's t-test assuming equal variances. The asterisk equals p<0.05, the double asterisk equals p<0.01, and the triple asterisk equals p<0.001,
using a two-tailed Student's t-test assuming equal variances. Error bars represent 1 standard deviation.
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698that VIMR6 represents a putative inhibitory cis-regulatory
element. In Figure 6, we show that combining VIMR6 with
VIMR2 decreased the number of eGFP positive Müller cells
by nearly 30% (compared to VIMR2-only levels), adding
further evidence that VIMR6 has the capacity to mitigate gene
expression. However, note that VIMR6 did not decrease MFI
levels. For the CD44 gene, the CD44R4 construct exhibited
similar negative-modulating characteristics as VIMR6.
Comparison of expression in two non-glial cell types: Six
experimental  constructs  (GLUL  500±UTR,  RLBP1
500±UTR, and S100b 500±UTR) were tested by transfection
in 3 cell types: wMC Muller cells, NIH/3T3 fibroblasts, and
Neuro-2a neuroblastoma cells (Figure 7). Both cell count and
MFI values for all constructs were normalized to pFUGW
expression levels. Under these culture conditions it is clear
that the promoter constructs tested do not restrict expression
to “glial” cells. After normalization to the pFUGW construct,
comparable  percentages  of  cells  (Figure  7A)  and  MFIs
(Figure 7B) were observed for wMC, NIH/3T3, and Neuro-2a
cells.  Overall  eGFP  positive  cell  counts  indicated  that
Neuro-2a  cells  were  significantly  more  receptive  to
transfection,  approaching  95%  transfection  efficiency
(compared to ~20% for both wMC and NIH/3T3 cells, using
an  identical  transfection  protocol;  data  not  shown).  Most
Figure  7.  Influence  of  cell  type  on
promoter-directed  reporter  gene
expression.  Promoter  constructs  were
transfected into wMC (rat Müller cells;
red),  NIH/3T3  (mouse  fibroblasts;
green),  or  Neuro-2a  (mouse
neuroblastoma; blue). All values were
normalized  to  pFUGW  and  plotted
according  to  percent  enhanced  green
fluorescent  protein  (eGFP)  positive
cells  (A)  or  mean  fluorescence
intensities (MFI; B). A: Percent eGFP
expressing cells are plotted for control
(pFUGW, pFTMGW, and VMR2) and
xperimental (GLUL 500 ± untranslated
region  (UTR),  S100B  500±UTR,  and
RLBP1 500±UTR) constructs. Note that
transfection efficiency of Neuro-2a cells
was significantly higher overall (95%
positive cells versus ~20% for wMC and
NIH/3T3),  which,  consequently,
resulted  in  significantly  higher
expression in the pFTM3GW control.
Nevertheless,  when  normalized  to
pFUGW, cell type had little influence on
the  relative  percentage  of  cells  that
express eGFP, with the exception of a
doubling  in  the  number  of  NIH/3T3
cells  transfected  with  the  RLBP1
500+UTR  construct.  B:  Though
absolute eGFP expression levels were
quite different for the three cell types
examined,  similar  results  to  those  in
(A) were obtained when the MFIs were
normalized  to  pFUGW.  Perhaps  an
overall  trend  is  noticeable;  NIH/3T3
cells  (green)  tended  to  offer  slightly
higher  relative  eGFP  expression,  and
Neuro-2a cells (blue) tended to exhibit
slightly  lower  eGFP  expression  than
that  observed  for  wMC  Müller  cells
(red). No TFX indicates no transfection.
Error  bars  represent  1  standard
deviation.
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699notably, a distinct difference was observed when NIH/3T3
cells were transfected with the RLBP1 500+UTR construct,
which resulted in over twice as many cells becoming eGFP
positive,  relative  to  the  pFUGW  control  (Figure  7A).  In
addition, it is noteworthy to point out that overall MFI levels
varied significantly for the three cell types: the average eGFP
intensities (arbitrary units) for the pFUGW constructs were
53.7, 9.7, and 86.5 for wMC, NIH/3T3, and Neuro-2a cells,
respectively. Thus, overall strength of transgene expression
appeared to be determined by the combination of promoter
activity  and  constitutive  (undetermined)  cellular  qualities.
Nevertheless, when normalized to pFUGW, the trend with the
experimental constructs was that wMC cells expressed the
eGFP  reporter  molecule  at  intermediate  levels,  generally
between that of NIH/3T3 and Neuro-2a cells.
DISCUSSION
We  believe  that  endogenous  delivery  of  neuroprotective
molecules by Müller glia, by way of viral-mediated gene
transfer, holds significant promise for slowing the progression
of  inherited  retinal  disease  [37–39].  Neurotrophic  factor
delivery  is  a  broad,  mutation-independent  approach  to
slowing the progression of neuronal cell loss in retinal damage
and  disease  [7,40,41].  An  important  consideration  when
delivering genetically encoded molecules is how to properly
regulate and control their expression once delivered to the
nucleus of a targeted cell.
In  an  attempt  to  identify  and  initially  characterize
functionally active regulatory elements capable of driving
transgene expression in Müller cells, we cloned promoter
constructs from nine Müller cell-associated genes into our
modified LV transfer vector, pFTM3GW (Figure 1). Our data
suggest  that  flow  cytometry-based  analysis  of
computationally  identified  regulatory  sequences  is  an
effective first step toward identifying small, gene-specific
promoters. Our data suggest that computationally identified
short ECR elements have the capacity to direct robust gene
expression, and that genetically diverse UTRs differentially
contribute to transgene expression. Finally, our data indicate
that combinatorial cloning of promoter fragments (from one
or more genes) may be exploited to facilitate fine-tuning of
therapeutic gene expression.
The RLBP1 and GLUL promoters exhibit robust gene
expression in our transfection assays. However, these two
genes, as an example, differ significantly with respect to the
influence of their respective UTRs. Only when the UTR is
combined with 5′ sequences (UTR+500, UTR+1500, or UTR
+ECR) do the RLBP1 constructs drive significant levels of
eGFP  expression  (Figure  2G).  The  number  of  eGFP
expressing cells and the MFIs of the combination constructs
are  higher  than  the  sum  of  the  expression  levels  of  the
individual elements. In contrast, the GLUL constructs were
minimally  influenced  by  the  inclusion  of  the  UTR  (only
slightly  higher  MFIs  with  the  UTR;  Figure  2E),  and  all
promoter constructs (with or without the associated UTR,
including a short 280 bp ECR) resulted in a high number of
eGFP positive cells. From these and other data, we conclude
that proximal regulatory and 5′ UTR sequences in and around
the gene’s “core promoter” likely operate in a gene-context
specific manner and have the capacity to function as more than
generic transcription initiation zones. Of course, it remains to
be determined how cell type specificity (of gene transcription)
is  influenced  by  “promoter”  shortening.  We  have  shown
previously  that  shortening  a  promoter  does  not,  a  priori,
sacrifice  gene  expression  specificity  [22].  However,  the
experiments presented here (Figure 7) suggest that, at least in
culture,  glial-associated  promoter  elements  do  have  the
capacity to express equally well in non-glial cell types, such
as NIH/3T3 fibroblasts and Neuro-2a neuroblastoma cells.
Analysis of CD44 and VIM ECRs indicates that promoter
activity can be modulated. Our data suggest that duplicating
(VIMR2/VIMR2)  or  combining  (CD44R2/VIMR2)  active
elements  in  the  same  construct  does  not  result  in  higher
transgene expression, as we had originally hypothesized. On
the contrary, adding ECRs to functional promoter elements
(VIMR2  and  CD44R2)  appeared  to  reduce  reporter  gene
expression when compared to the single-element constructs
(Figure  6).  In  the  case  of  the  VIMR2/VIMR2  construct,
duplicating the same element actually reduced expression by
~15%, suggesting a possible competition for transcription
factor binding sites. It seems reasonable to hypothesize that
providing  additional  spacing  between  promoter  elements
(including  small  “stuffer”  sequences)  may  improve
accessibility of transcription factors, but this has yet to be
tested. It will be important to determine if individual ECRs
can be combined to increase transgene expression in future
studies.
Including the VIMR6 element in a combination construct
(VIMR6/VIMR2;  Figure  6)  also  reduced  reporter  gene
expression, similar to the influence of this element on the
empty vector (Figure 5). These data suggest that VIMR6 may
function as a “partial repressor” and could conceivably be
included in future constructs to reduce expression levels of
active promoters. Importantly, reversing the orientation of the
VMR2 construct (VIMR2-Reverse; Figure 6) failed to drive
gene expression, reaffirming the expectation that promoter
orientation is critical for directed gene expression. Lastly, and
interestingly, 3′ UTR constructs from the VIM gene (VIMR7
and VIMR8) drove eGFP expression nearly as well as the 5′
UTR  (VIMR2).  Future  experiments  will  test  additional
combinations of ECRs, 5′ UTRs, and 3′ UTRs from other
genes, as well as the resultant cellular specificity of such
constructs. Thus, we believe that pFTM3GW is a powerful
tool that enhances our ability to examine multiple regulatory
elements in single promoter constructs, which will enable
detailed testing and analysis of in silico and in vitro engineered
regulatory constructs.
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700We have shown previously [22] that quantification of
eGFP using flow cytometry is as accurate as quantitative RT–
PCR  analysis.  Moreover,  flow  cytometry  analysis  of
transfected cells is faster, cheaper, and less labor intensive
than  quantitative  RT–PCR,  and  therefore  improves
quantitative throughput and analysis of promoter-regulated
gene expression. Importantly, though, microscopic screening
of transfected cells is a very rapid and reliable method to
quickly and qualitatively assess promoter strength (see Figure
3). Our transfection data suggest that 1) both 5′ and 3′ UTRs
can impart generally positive influences on gene expression;
2) short DNA sequences (500 bp or less) can drive expression
levels as robustly as the longer, canonical promoters; and 3)
combinations  of  regulatory  elements  can  measurably
influence promoter activity. Future experiments will focus on
characterizing  promoter  cell-specificity  and  assessing  the
concordance of expression levels between in vitro and in vivo
experimental assays.
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703Appendix 1. Full-length and proximal promoter fluorescence data, genomic
fragment locations, and primer sequences.
To access the data, click or select the words “Appendix
1.” We identified and cloned the full-length promoters (~1500
bp), proximal promoter regions (~500 bp), the most proximal
evolutionarily conserved regions (ECRs) to the transcription
start site for each of nine genes identified in the literature as
being potential or known Müller cell markers: CAR2, CD44,
CRALBP,  GFAP,  GLUL,  PDGFRA,  S100B,  SLC1A3,  and
VIM. The sequences were cloned either including or excluding
the UTR, and then evaluated with fluorescent microscopy and
flow cytometry. The table shows the eGFP expression and the
mean  fluorescent  intensity,  with  values  normalized  and
expressed as fold change relative to pFTM3GW. Restriction
endonuclease is abbreviated REN. The “†” symbol identifies
small UTRs that were not individually tested. The “‡” symbol
denotes  very  large  UTRs;  only  the  ~200  bp  regions
immediately following the TSS were analyzed. eGFP and MFI
values are shown as fold change relative to pFTM3GW vector
alone. An (R) denotes that gene is arranged in a “reversed”
orientation (3′-5′) relative to the chromosome’s centromere.
The  “§”  symbol  denotes  ECR  not  located  immediately
proximal to the TSS, and some intervening sequence was
included  in  ECR+UTR  constructs.  “NM”numbers
immediately below the gene acronym refer to RefSeq mRNA
ID numbers.
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704Appendix 2. Additional evolutionarily conserved region fluorescence data,
genomic fragment locations, and primer sequences.
To access the data, click or select the words “Appendix
2.” Additional evolutionarily conserved regions (ECR) from
CD44 and vimentin (VIM) were further studied; 32 sequences
were PCR amplified from C57BL/6J mouse and Sprague-
Dawley rat genomic DNAs, cloned into the pFTMGW vector,
and transfected into cultured rat Müller cells. The sequences
were  initially  screened  by  fluorescence  microscopy.
Subsequently, eGFP positive constructs were analyzed by
flow cytometry. The table shows the eGFP expression and the
mean fluorescent intensity (MFI), with values normalized and
expressed  as  fold  change  relative  to  pFTMGW  alone.
Restriction endonuclease is abbreviated REN. The “†” symbol
identifies referenced in Geller et al. (2007) [22] as Vim409.
The “‡” (nd) denotes flow cytometry was not performed on
constructs showing eGFP expression qualitatively similar to
vector (pFTMGW) alone. eGFP and MFI values are shown as
fold change in expression relative to pFTMGW vector alone.
An  (R)  denotes  that  gene  is  arranged  in  a  “reversed”
orientation (3′-5′) relative to the chromosome’s centromere.
The “#” symbol represents that tested in combination with
VIMR2 or CD44R2; Figure 6. The “^” symbol denotes cloned
and tested in reverse orientation; Figure 6. The “@” denotes
sequence includes the 5′ UTR, the first protein coding exon,
and part of the first intron. “NM” numbers immediately below
the gene acronym refer to RefSeq mRNA ID numbers.
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